Switzerland-listed chocolate maker Nestlé has made a corporate venturing investment of undisclosed size in Accera, which provides milkshakes for people with Alzheimer’s disease.

Luis Cantarell, president and chief executive of Nestlé Health Science, a subsidiary set up by the Swiss company last year, said: “The significance of this is not the [undisclosed] size of the investment, but the fact that it is our first step in developing our brain health portfolio.”

In December 2010, Accera, which also makes drugs for Nestlé’s pet food, raised €8m ($11m), according to a regulatory filing first seen by CB Insights.

Inventages Venture Capital, a Switzerland-based venture capital firm backed by Nestlé, and Posco BioVentures, the corporate venturing unit of Korean steelmaker Posco, had backed its three previous rounds.

Wolfgang Reichenberger and Gunnar Weikert, co-heads of Inventages, are also on Accera’s board.

Accera previously raised $35m in its series C round in November 2008…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?